MuDRA-Based Virtual Screening of Terpenes for Anti-Leishmania Infantum Activity: In Vitro Validation and Mechanistic Insights from Molecular Docking

• Published in: ChemMedChem 2024-11, p.e202400743
• Main Authors: Barros de Menezes, Renata Priscila, Ferreira de Sousa, Natália, Herrera-Acevedo, Chonny, Santos Aquino de Araújo, Rodrigo, Durand Trigueiro Lira, Nikole, Fechine Tavares, Josean, Jorge Kato, Massuo, Alex da Rocha Coelho, Francisco, Sousa Dos Santos, Airton Lucas, Antonio da Franca Rodrigues, Klinger, Bezerra Mendonça-Júnior, Francisco Jaime, Scotti, Luciana, Tullius Scotti, Marcus
• Format: Article
• Language: English
• ISSN: 1860-7179; 1860-7187; 1860-7187
• DOI: 10.1002/cmdc.202400743

Leishmaniasis, caused by Leishmania parasites, presents a major global health challenge due to limitations of existing treatments, including toxicity, side effects, drug resistance, and high costs. This study utilized the MuDRA (Multi-Descriptor Read Across) model for virtual screening to identify potential anti-Leishmania infantum compounds. A set of 15 terpenes and steroids was screened, leading to the identification of four promising candidates-lupeol, xylodiol, morolic acid, and trachyloban-18-oic acid. These compounds demonstrated significant activity in both virtual screening and in vitro assays. To elucidate their potential mechanisms of action, we conducted molecular docking and dynamics studies, which revealed stable interactions with key target enzymes, such as trypanothione reductase and 14-alpha demethylase (CYP51), crucial to the parasite's survival and pathogenesis. These findings provide valuable insights into novel mechanisms for targeting leishmaniasis, offering a promising basis for the development of new therapeutics. The integration of computational and experimental methods in this study not only advances our understanding of potential anti-leishmanial agents but also highlights the effectiveness of this approach in discovering new drugs for neglected diseases. Further in vivo studies and clinical trials will be essential to validate the therapeutic potential of these.